EFFICACY OF ABATACEPT IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目前治疗SSc的选择显示出有限的疗效。尽管SSC的病因尚不清楚，但一些观察支持活化的T细胞在疾病发病机制中的作用。Abatacept通过与CD80和CD86结合来阻断T细胞的激活，从而阻断与CD28的相互作用。这项研究将评估阿巴塔塞特治疗SSc的安全性和有效性，可能为SSc患者提供一种新的治疗选择。此外，通过检查患者血液和皮肤中存在并激活的细胞和基因，将进一步了解疾病的病因。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current therapeutic options for SSc have shown limited efficacy. Although the etiology of SSc remains unknown, several observations support the role of activated T cells in disease pathogenesis. Abatacept blocks T cell activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This study will evaluate the safety and efficacy of abatacept treatment for SSc potentially revealing a new treatment option for patients with SSc. In addition, further insight into the etiology of the disease will be gained from examination of cells and genes present and activated in both the blood and skin of patients.